Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bimba F Hoyer

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
Frontiers in Immunology|April 5, 2021
Patient Reported Outcomes in Chronic Inflammatory Diseases: Current State, Limitations and PerspectivesFlorian Tran, Jan Henrik Schirmer, Ilka Ratjen, et al.
Journal of Autoimmunity|June 26, 2012
Bone marrow of NZB/W mice is the major site for plasma cells resistant to dexamethasone and cyclophosphamide: implications for the treatment of autoimmunityImtiaz M Mumtaz, Bimba F Hoyer, Daniel Panne, et al.
Annals of the Rheumatic Diseases|September 29, 2011
Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximabBimba F Hoyer, Imtiaz M Mumtaz, Konstanze Loddenkemper, et al.
Clinical and Experimental Rheumatology|April 6, 2021
Do patients with rheumatoid arthritis show a different course of COVID-19 compared to patients with spondyloarthritis?Rebecca Hasseli, Alexander Pfeil, Bimba F Hoyer, et al.
RMD Open|September 4, 2020
National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRDRebecca Hasseli, Ulf Mueller-Ladner, Tim Schmeiser, et al.
RMD Open|January 22, 2021
Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseasesRebecca Hasseli, Ulf Mueller-Ladner, Bimba F Hoyer, et al.
RMD Open|October 21, 2021
TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMDAnne Constanze Regierer, Rebecca Hasseli, Martin Schäfer, et al.
Zeitschrift Fur Rheumatologie|January 4, 2023
[Immune-mediated inflammatory diseases in Germany : A cross-sectional analysis of comorbidities and pharmacotherapy]Jan Leipe, Renate Schmelz, Gabriela Riemekasten, et al.
Arthritis Care & Research|September 28, 2019
Associations Between Classification Criteria Items in Systemic Lupus ErythematosusZahi Touma, Ricard Cervera, Ralph Brinks, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 24, 2018
Brief Report: How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification CriteriaMarta Mosca, Karen H Costenbader, Sindhu R Johnson, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Frontiers in Immunology|April 5, 2021
Patient Reported Outcomes in Chronic Inflammatory Diseases: Current State, Limitations and PerspectivesFlorian Tran, Jan Henrik Schirmer, Ilka Ratjen, et al.
Journal of Autoimmunity|June 26, 2012
Bone marrow of NZB/W mice is the major site for plasma cells resistant to dexamethasone and cyclophosphamide: implications for the treatment of autoimmunityImtiaz M Mumtaz, Bimba F Hoyer, Daniel Panne, et al.
Annals of the Rheumatic Diseases|September 29, 2011
Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximabBimba F Hoyer, Imtiaz M Mumtaz, Konstanze Loddenkemper, et al.
Clinical and Experimental Rheumatology|April 6, 2021
Do patients with rheumatoid arthritis show a different course of COVID-19 compared to patients with spondyloarthritis?Rebecca Hasseli, Alexander Pfeil, Bimba F Hoyer, et al.
RMD Open|September 4, 2020
National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRDRebecca Hasseli, Ulf Mueller-Ladner, Tim Schmeiser, et al.
RMD Open|January 22, 2021
Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseasesRebecca Hasseli, Ulf Mueller-Ladner, Bimba F Hoyer, et al.
RMD Open|October 21, 2021
TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMDAnne Constanze Regierer, Rebecca Hasseli, Martin Schäfer, et al.
Zeitschrift Fur Rheumatologie|January 4, 2023
[Immune-mediated inflammatory diseases in Germany : A cross-sectional analysis of comorbidities and pharmacotherapy]Jan Leipe, Renate Schmelz, Gabriela Riemekasten, et al.
Arthritis Care & Research|September 28, 2019
Associations Between Classification Criteria Items in Systemic Lupus ErythematosusZahi Touma, Ricard Cervera, Ralph Brinks, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 24, 2018
Brief Report: How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification CriteriaMarta Mosca, Karen H Costenbader, Sindhu R Johnson, et al.
Pageof 5